Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
February 27, 2024 at 06:00 am
Share
Tarsus Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 13.08 million compared to USD 10 million a year ago. Net loss was USD 41.9 million compared to USD 13.6 million a year ago.
Basic loss per share from continuing operations was USD 1.31 compared to USD 0.51 a year ago.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Companyâs lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.